Get started
Work

Reviewing The Status Of Backup Hematopoietic Stem Cells (HSC) Banking For Multiple Myeloma (MM) Patients Who Are Eligible For Autologous Hematopoietic Stem Cells Transplant (AHSCT) In This Poor Economy

Year: 2010
Type: article
Abstract: Novel drugs combinations have demonstrated response rates similar to AHSCT. Due to lack of long term follow up, impact of these novel agents on HSC mobilization is unknown. AHSCT is still standard therapy for newly diagnosed MM. There are randomized trials underway to better define the role and timing of AHSCT in MM. Due to this uncertainty with novel agents, arbitrary recommendations are made to cryopreserve backup stem cells for pts who want to postpone AHSCT & to collect additional HSC at 1st HSC collection for future use.
DOI: 10.1016/j.bbmt.2009.12.173
Authors: M.H. Abidi, I.L. Woldie, R. Goveas, V. Ratanatharathorn, Z. Al-Kadhimi, J. Abrams, L. Ayash, L. Lum, J. Uberti
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2009976846
FWCI:
Cites:
Cited by:
Related to: 10